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Capecitabine, an oral ﬂuoropyrimidine carbamate, was designed to generate 5-ﬂuorouracil preferentially at the tumour site.
This randomised, phase II trial evaluated the efﬁcacy and safety of capecitabine or paclitaxel in patients with anthracycline-
pretreated metastatic breast cancer. Outpatients with locally advanced and/or metastatic breast cancer whose disease was
unresponsive or resistant to anthracycline therapy were randomised to 3-week cycles of intermittent oral capecitabine
(1255 mg m
72 twice daily, days 1–14, (22 patients)) or a reference arm of i.v. paclitaxel (175 mg m
72, (20 patients)). Two
additional patients were initially randomised to continuous capecitabine 666 mg m
72 twice daily, but this arm was closed
following selection of the intermittent schedule for further development. Overall response rate was 36% (95% CI 17–59%)
with capecitabine (including three complete responses) and 26% (95% CI 9–51%) with paclitaxel (no complete responses).
Median time to disease progression was similar in the two treatment groups (3.0 months with capecitabine, 3.1 months with
paclitaxel), as was overall survival (7.6 and 9.4 months, respectively). Paclitaxel was associated with more alopecia, peripheral
neuropathy, myalgia and neutropenia, whereas typical capecitabine-related adverse events were diarrhoea, vomiting and
hand–foot syndrome. Twenty-three per cent of capecitabine-treated patients and 16% of paclitaxel-treated patients achieved
a 510% improvement in Karnofsky Performance Status. Oral capecitabine is active in anthracycline-pretreated advanced/
metastatic breast cancer and has a favourable safety proﬁle. Furthermore, capecitabine provides a convenient, patient-
orientated therapy.
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Every year more than 425000 women in Europe and the USA are
diagnosed with breast cancer (Black et al, 1997; Landis et al, 1999),
nearly half of whom will develop metastatic disease (Lippman,
1998). The prognosis for women with metastatic and/or advanced
disease is poor, with a median survival time of approximately 18 to
30 months from diagnosis (Perez, 1998). In these circumstances,
the primary goal of therapy is palliation (Hortobagyi, 1998; Blum,
1999; Parﬁtt, 1999) and treatment usually involves hormonal therapy
or chemotherapeutic agents (Hortobagyi, 1998; Marty et al, 1999).
The widespread use of anthracycline-containing regimens as
adjuvant and ﬁrst-line treatment for breast cancer has resulted in
an increase in the number of patients presenting with disease that
is resistant to anthracyclines (Marty et al, 1999). The use of M-
phase inhibitors such as taxanes and vinorelbine in these patients
is widely accepted. Response rates of 22 to 28% are reported for
paclitaxel (Perez, 1998), 29 to 41% for docetaxel (Bonneterre et
al, 1999; Trudeau, 1999) and 15 to 16% for vinorelbine in this
setting (Degardin et al, 1994; Ibrahim et al, 1999). The duration
of remission is approximately 4 to 5 months (Degardin et al,
1994; Ibrahim et al, 1999).
Capecitabine (Xeloda
1) is a tumour-selective ﬂuoropyrimidine
carbamate designed to mimic continuous infusion 5-FU and to
generate 5-FU preferentially in tumour tissue by exploiting the
higher concentrations of thymidine phosphorylase (TP) found in
malignant cells compared with normal cells (Miwa et al, 1998).
Following oral administration, capecitabine passes intact through
the intestinal mucosa and is rapidly and extensively metabolised
via a sequential triple enzyme pathway. Capecitabine and its inter-
mediate metabolites are not cytotoxic, and require conversion to 5-
FU by TP. Moreover, since elevated TP concentrations correlate
with a poor prognosis in breast cancer patients (Toi et al, 1997),
capecitabine may be particularly effective in this group of patients
(Frings, 1998).
The selective tumour activation of capecitabine has been
conﬁrmed in a trial of patients with colorectal cancer (Schu ¨ller et
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twice daily for 5 to 7 days before surgical resection of their primary
tumour or metastatic lesions. Concentrations of 5-FU were found
to be 3.2-fold higher in primary colorectal tumour tissue than in
adjacent healthy tissue and 21 times higher than in plasma. Cape-
citabine has demonstrated considerable clinical activity in patients
with heavily-pretreated, paclitaxel-resistant metastatic breast cancer,
a patient population that previously had no established treatment
options. In a phase II trial in this setting, capecitabine therapy
resulted in a 20% response rate (with an additional 43% of patients
achieving stable disease) and a median survival exceeding 1 year
(Blum, 1999).
As an oral agent, capecitabine avoids the complications asso-
ciated with continuous infusion 5-FU, including the need for
central venous access and the medical complications this can intro-
duce such as thrombosis, bleeding, infection and pneumothorax. In
addition, oral agents are preferred by patients and may provide
pharmaco-economic beneﬁts (Liu et al, 1997; Borner et al, 2000).
The primary objective of the present study was to evaluate the
overall response rate to capecitabine given either intermittently
or continuously to female patients with advanced and/or metastatic
breast cancer who either had failed or were resistant to treatment
with an anthracycline-containing regimen. A standard, 3-h infusion
of paclitaxel every 3 weeks, an approved and effective second-line
therapy (Perez, 1998), was included in the study as a reference
arm to minimise recruitment bias. Secondary objectives were to
determine and evaluate additional efﬁcacy parameters and the
safety proﬁle of each treatment arm.
PATIENTS AND METHODS
Eligibility
The study included female patients (518 years old) with histolo-
gically or cytologically conﬁrmed advanced and/or metastatic
breast cancer. Initially, patients could have been treated with only
one anthracycline-containing chemotherapy regimen in the adju-
vant or metastatic setting. To increase recruitment, this was
amended to include patients treated with 42 regimens for meta-
static disease, the last regimen containing an anthracycline. All
patients were either anthracycline resistant (relapse within 6
months of completion of adjuvant therapy, initial response
followed by disease progression while on the same therapy or
disease progression on therapy without evidence of objective
response) or anthracycline failing (stable disease after a minimum
of four cycles, complete or partial response followed by disease
progression within 12 months of treatment, or relapse 6 to 12
months after completion of anthracycline-based adjuvant treat-
ment). Patients had at least one bidimensionally measurable
lesion that had not been previously irradiated (new lesions in
previously irradiated ﬁelds were accepted). Bone lesions, ascites
and pleural effusions were not considered measurable. Patients
were required to have a minimum indicator lesion size of
520 mm for liver, soft tissue or other masses, or 510 mm in
lung, skin lesions or lymph nodes. Further inclusion criteria
included a life expectancy of 53 months and a Karnofsky Perfor-
mance Status of 570%.
Patients who had received prior treatment with taxanes or
continuous/protracted administration of ﬂuoropyrimidines were
excluded. Patients with brain metastases were also excluded, as
were patients who lacked physical integrity of the gastrointestinal
tract or patients with malabsorption syndromes. Depressed bone
marrow function (haemoglobin 59.0 g dl
71; granulocyte count
51.5610
9 l
71; platelet count 5100610
9 l
71) and signiﬁcant
cardiac disease were excluded. Patients were not eligible for the
study if screening evaluations revealed signiﬁcant abnormalities
in serum creatinine (51.56upper normal limit), serum bilirubin
(51.56upper normal limit), alanine aminotransferase
(ALT), aspartate aminotransferase (AST) or alkaline phosphatase
(42.56upper normal limit or 456upper normal limit in the
case of liver metastases for all three parameters). Up to 106upper
limit of normal for alkaline phosphatase concentrations was
permitted in patients with bone disease.
All patients provided written, informed, consent and the study
was performed according to the Declaration of Helsinki and
current amendments, and to the principles of Good Clinical Prac-
tice. The protocol and all amendments were approved by the
appropriate research ethics committees.
Study design and randomisation
The primary objective of this multicentre, open-label, randomised
study was to evaluate the objective response rate to capecitabine
therapy in patients with advanced and/or metastatic disease that
had progressed following anthracycline treatment. Secondary objec-
tives were to evaluate and compare the safety proﬁles of the three
treatment arms and to determine and compare the efﬁcacy proﬁles
of the three treatment groups in terms of time to response, dura-
tion of response and time to disease progression.
Patients were randomised to three treatment arms in a 1:1:1
ratio. Patients were stratiﬁed according to anthracycline resistance
or failure, as deﬁned previously. Capecitabine was administered
in 3-weekly cycles, continuously (666 mg m
72 twice daily without
interruption) or intermittently (1255 mg m
72 twice daily, 2 weeks
treatment followed by 1 weeks rest), for at least two cycles. Cape-
citabine was taken twice daily at 12+2-h intervals, within 30 min
of breakfast and dinner, with water, rounded to the nearest dose
that could be administered using 500 mg and 150 mg tablets. Pacli-
taxel 175 mg m
72 was administered as a 3-h i.v. infusion every 3
weeks, with appropriate premedication.
Study assessments and analysis
Screening assessments were conducted within 2 weeks prior to the
start of treatment and included medical history and general physi-
cal examinations, electrocardiogram and tumour assessment (CT
scan, chest X-ray, bone scan and X-rays). Assessment of vital signs,
physical measurements and general laboratory tests were conducted
within 1 week prior to the start of treatment.
Tumour response was assessed based on World Health Organi-
zation (WHO) criteria (WHO Handbook, 1979) at screening, at
weeks 6, 12 and 18, and at treatment discontinuation. In patients
with objective tumour regression or stable disease who continued
treatment beyond 18 weeks, subsequent tumour response was
assessed at the discretion of the investigator. The primary endpoint
was overall response rate (complete or partial response as best
response). The secondary endpoints were deﬁned as follows: time
to disease progression (interval between ﬁrst day of treatment
and ﬁrst recording of disease progression or death); time to
response (interval between treatment start and the day a response
(in conﬁrmed responders) was ﬁrst recorded); and duration of
response in patients with complete or partial response (interval
between treatment start and the ﬁrst recording of disease progres-
sion).
Adverse events (graded as mild, moderate, severe or life threa-
tening according to National Cancer Institute of Canada
Common Toxicity Criteria, (NCIC CTC)) were recorded up to
28 days after the last dose of study drug. Hand–foot syndrome
was graded 1–3 (Blum et al, 1999a).
Dose modiﬁcations
Treatment interruption or dose reduction was not indicated for
reactions unlikely to become serious or life threatening, for exam-
ple alopecia. In patients receiving capecitabine, treatment was
interrupted in the event of toxicities classiﬁed as grade 2 or higher.
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outlined in Table 1.
In patients receiving paclitaxel who had a neutrophil count
51500 cells mm
73 and/or platelet count 5100000 mm
73 on
the day scheduled for the next administration of treatment, therapy
was delayed until recovery of neutrophil count 51500 cells mm
73
and platelet count 5100000 mm
73. The paclitaxel dose was
reduced to 135 mg m
72 if patients experienced any of the follow-
ing adverse events: febrile neutropenic episode, granulocyte count
5500 cells mm
73 for 515 days, platelet count 550000 mm
–3
associated with bleeding or platelet count 525000 mm
73 with
or without an episode of bleeding. If these toxicities recurred
during a subsequent treatment cycle, the paclitaxel dose of
135 mg m
72 was further reduced by 25%. For all other toxicities
dose modiﬁcations were the same as for capecitabine (Table 1).
Patients with major hypersensitivity were withdrawn from study
treatment.
Statistical analysis
Descriptive analyses of efﬁcacy and standard safety summaries were
performed. Best overall responses were summarised by response
rates and 95% Pearson–Clopper conﬁdence intervals. Duration
of response is analysed according to WHO criteria. It was planned
to analyse time to disease progression or death, survival, duration
of response and time to response according to Kaplan–Meier esti-
mates, with survival and time to disease progression curves
compared using the log-rank test. However, owing to the prema-
ture discontinuation of the trial, these analyses were not
performed.
The planned sample size of 102 evaluable patients allowed for 34
patients to be randomised to each treatment arm. Following
discontinuation of the continuous capecitabine arm (after inclusion
of two patients in this arm), it was planned to close patient recruit-
ment after enrolment of a total of 76 patients or 68 evaluable
patients. Data were analysed and compared only for patients in
the intermittent capecitabine and paclitaxel groups. The number
of patients in the continuous capecitabine group (two) was too
small for meaningful analysis.
RESULTS
Patient demography and disposition
The study was conducted from May 1996 to March 1997 at 18
centres in Australia, Belgium, Canada, France, Poland, Russia,
Spain, the UK and the USA. During recruitment, data from a
randomised, phase II study in colorectal cancer patients led to
the selection of the intermittent capecitabine regimen for further
clinical development (Van Cutsem et al, 2000), and therefore
recruitment to continuous capecitabine treatment in the present
study was stopped, creating a two-arm study. The recruitment
target was 76 patients or 68 evaluable patients. This target was
not reached because of clear preferences of the patients for either
an oral investigational drug or an i.v. drug with established efﬁcacy.
Forty-four patients were randomised, 22 to intermittent capecita-
bine, 20 to paclitaxel and two to continuous capecitabine
treatment. Owing to brain metastases diagnosed 1 day after rando-
misation, one patient randomised to paclitaxel never received
treatment, and therefore this patient is not included in the treat-
ment analysis.
Table 2 summarises the baseline demographic and tumour char-
acteristics, which were well balanced between treatment arms. All
but two patients had 52 (median two, range one to seven) meta-
static sites. Almost all patients (86%) had received prior
chemotherapy with cyclophosphamide, 61% had been treated with
5-FU-containing regimens and 68% had received anti-oestrogens.
Twenty-four patients discontinued treatment during the 18-week
study period, with similar proportions discontinuing from the
intermittent capecitabine (54%) and paclitaxel (63%) arms. The
most frequent reason for treatment discontinuation was insufﬁcient
response/disease progression (66% of patients who discontinued
therapy in both treatment arms). Ten of the 22 intermittent cape-
citabine patients and seven of the 19 paclitaxel patients completed
the 18-week study period.
Efﬁcacy
The best response achieved during the treatment period was deter-
mined for the intent-to-treat population, and results are presented
in Table 3. The primary endpoint, overall response rate (complete
or partial response), was 36% (95% CI 17–59%) in the capecita-
bine group and 26% (95% CI 9–51%) in the paclitaxel group (not
statistically different). Moreover, complete responses occurred in
three patients treated with intermittent capecitabine but no
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Table 1 Schedule of dose reductions/interruptions in the event of capecitabine-related toxicity
Grade 2 Grade 3 Grade 4
First appearance Treatment interrupted until resolved to grade
0–1, then continued at same dose with
prophylaxis if possible
Treatment interrupted until resolved to grade
0–1, then continued at 75% of original dose
with prophylaxis if possible
Treatment discontinued unless it was felt to be
in the best interest of the patient to continue at
50% of the original dose once the toxicity had
resolved to grade 0–1
Second appearance Treatment interrupted until resolved to grade
0–1, then continued at 75% of original dose
Treatment interrupted until resolved to grade
0–1, then continued at 50% of original dose
Treatment discontinued
Third appearance Treatment interrupted until resolved to grade
0–1, then continued at 50% of original dose
Treatment discontinued
Fourth appearance Treatment discontinued
Table 2 Baseline characteristics of the intent-to-treat population
Intermittent
capecitabine Paclitaxel
(%) (%)
(n=22) (n=19)
Median age (years) (range) 52.0 (33–67) 52.0 (27–73)
Median Karnofsky performance status (%) 82.5 (70–100) 80.0 (80–100)
(range)
Prior 5-FU therapy 14 (67) 11 (58)
Anthracycline-failing patients 13 (59) 10 (53)
Anthracycline-resistant patients 9 (41) 9 (47)
Number of metastatic sites
10 1 1
22 7 3 7
33 2 2 1
45 0
51 8 2 6
451 8 5
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1367–1372patients in the paclitaxel group. In both treatment arms, responses
generally occurred early in the course of treatment (week 6 or week
12 assessments), with the exception of one patient in the paclitaxel
arm who ﬁrst showed a response at week 18.
At the time of database closure, disease had progressed in three
of the responding patients in each group. Disease progression was
recorded at days 118, 187 and 288 in the capecitabine patients and
days 178, 197 and 288 in the paclitaxel patients. Response duration
was in excess of 18 weeks in ﬁve patients treated with capecitabine
and two patients treated with paclitaxel. The median duration of
response was in excess of 9.4 months in both treatment groups.
Time to disease progression was similar in the two treatment
groups (median 3.0 months (95% CI 1.4–6.6) with capecitabine
and 3.1 months (95% CI 2.5–6.5) with paclitaxel). Overall survival
was similar in the two treatment groups (median 7.6 months, 95%
CI 3.5–13.5 with capecitabine; 9.4 months, 95% CI 6.1–10.2 with
paclitaxel).
Safety
In both treatment arms almost all patients experienced treatment-
related adverse events. Paclitaxel was typically associated with
alopecia, paraesthesia, peripheral neuropathy and myalgia, whereas
capecitabine was associated with more diarrhoea, vomiting and
hand–foot syndrome. The incidence of nausea and stomatitis
was similar in the two treatment arms (Table 4). The overall inci-
dence of treatment-related grade 3 adverse events was 58% with
paclitaxel and 23% with capecitabine. Grade 3 adverse events
reported in the capecitabine group were: nausea (two cases),
vomiting (two cases), hand–foot syndrome (two cases), constipa-
tion and neutropenia reported by the investigator as a clinical
adverse event requiring medical intervention (one case each). In
the paclitaxel arm, grade 3 adverse events were alopecia (ﬁve cases),
and one each of paraesthesia, stomatitis, diarrhoea, vomiting, asth-
enia, pain, musculoskeletal pain and anaemia. There were four
treatment-related grade 4 events in three patients: abdominal pain
and diarrhoea (one capecitabine patient), aplasia reported by the
investigator as a clinical adverse event (one paclitaxel patient)
and neutropenia as a clinical adverse event (one paclitaxel patient).
A major difference between treatments concerned the incidence
of grade 3/4 haematologic abnormalities, with substantially less
myelosuppression reported in the capecitabine group (Table 5).
The incidence of grade 3/4 shifts in neutropenia was markedly
higher in the paclitaxel arm than in patients receiving capecitabine
(53% vs 9%, respectively). There were no grade 3 or 4 shifts from
baseline in alanine aminotransferase, aspartate aminotransferase,
alkaline phosphatase, or bilirubin, except for one grade 3 shift in
ALT in a patient receiving paclitaxel.
Five patients receiving intermittent capecitabine required treat-
ment interruption and/or modiﬁcation, but not discontinuation,
to control the following adverse events: neutropenia (one patient),
hand–foot syndrome (two patients), pyrexia (one patient) and
hypotension plus pyrexia (one patient). No patients withdrew from
capecitabine treatment because of adverse events. One paclitaxel
patient required dose modiﬁcation for neutropenia. In addition,
treatment was discontinued in one patient receiving paclitaxel
owing to treatment-related nausea and vomiting. There were no
treatment-related deaths in either group. At database closure, 14
patients in the capecitabine arm and nine patients in the paclitaxel
group had died.
Karnofsky Performance Status scores were generally stable or
decreased moderately (10–20%) during the study. One paclitaxel
patient had a clinically relevant decrease (440%) in performance
status. Improvement from baseline of 520% was reported in three
patients in the capecitabine group. A further two patients receiving
capecitabine and three patients receiving paclitaxel showed 510%
increases.
DISCUSSION
In this randomised, phase II study the continuous capecitabine
treatment arm was abandoned following selection of the intermit-
tent capecitabine regimen for further development. This selection
was based on the results of a randomised, phase II trial in 109
colorectal cancer patients, in which intermittent capecitabine
resulted in a more favourable time to disease progression than
the other regimens tested. The intermittent schedule also exhibited
an acceptable toxicity proﬁle over a wider dose range than the
continuous regimen, enabled exposure to a higher dose intensity
and included a 1-week drug-free period, which was considered
more appealing to patients. In addition to the discontinuation of
one treatment arm, the present study did not reach the target
patient number owing to recruitment issues. Candidate patients
expressed a strong preference for either the investigational oral
agent or the established i.v. treatment and therefore refused to be
randomised.
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Table 3 Summary of overall tumour response rates
Intermittent
capecitabine Paclitaxel
(%, (95% CI)) (%, (95% CI))
(n=22) (n=19)
Overall response rate 8 (36 (17–59)) 5 (26 (9–51))
Complete response 3 (14 (3–35)) 0
Partial response 5 (23 (8–45)) 5 (26 (9–51))
Stable disease 5 (23 (8–45)) 9 (47 (24–71))
Progressive disease 8 (36 (17–59)) 5 (26 (9–51))
Missing post-baseline information* 1 (5 (0–23)) 0
*Patient refused further therapy after 8 days of treatment.
Table 4 Summary of most common (515%) non-haematological treat-
ment-related adverse events
Intermittent
capecitabine Paclitaxel
(%) (n=22) (%) (n=19)
Patients with treatment-related adverse events 21 (96) 18 (95)
Nausea 10 (46) 6 (32)
Alopecia 0 9 (47)
Diarrhoea 9 (41) 3 (16)
Vomiting 9 (41) 3 (16)
Paraesthesia 0 6 (32)
Fatigue 6 (27) 3 (16)
Stomatitis 5 (23) 4 (21)
Pyrexia 5 (23) 2 (11)
Hand-foot syndrome 4 (18) 0
Myalgia 0 5 (26)
Peripheral neuropathy 0 3 (16)
Table 5 Summary of most common haematological toxicities (grade 3/4
shifts from baseline)
Intermittent
capecitabine (%) Paclitaxel (%)
(n=22) (n=19)
Neutropenia (grade 3/4) 9 53
Neutropenia (grade 4) 0 26
Leukocytopenia (grade 3) 0 21
Thrombocytopenia (grade 3) 0 5
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an intermittent regimen, shows similar efﬁcacy to paclitaxel in
patients with metastatic and/or advanced breast cancer previously
exposed to anthracyclines. The tumour response rate was 36% in
patients treated with intermittent capecitabine and 26% in patients
treated with paclitaxel, although the conﬁdence intervals over-
lapped, owing to the small sample sizes. Moreover, three patients
treated with capecitabine, but no patients in the paclitaxel arm,
achieved complete responses. Responses tended to occur earlier
in patients receiving capecitabine. The other secondary variables
indicated similar efﬁcacy in the two treatments. The validity of this
comparison is supported by the response rate for paclitaxel
patients, which was within the 22 to 28% range reported in the
literature (Perez, 1998).
Almost two-thirds of patients (61%) had received prior treat-
ment with bolus 5-FU, indicating that capecitabine may be useful
in the treatment of patients whose disease has progressed during
or following 5-FU therapy. This observation is consistent with
results of preclinical studies, which indicated that capecitabine
has anti-tumour activity even in cell lines that are resistant to 5-
FU (Cao et al, 1997). There is some evidence of a correlation
between high TP activity and resistance to 5-FU (Danenberg et
al, 1997). Therefore, a consequence of the unique, TP-mediated
mechanism of action of capecitabine may be incomplete cross-
resistance to conventional 5-FU in tumours overexpressing TP.
The high activity of intermittent capecitabine in pretreated
breast cancer has been observed in two other phase II trials in
metastatic/advanced breast cancer patients who had failed or were
resistant to taxane therapy. In the ﬁrst trial, which included 162
patients (Blum et al, 1999a), the overall response rate was 20%
(with a further 43% achieving stable disease) and the median survi-
val was 12.6 months. Additionally, 47% of patients with signiﬁcant
pain at baseline showed a durable reduction in pain scores of at
least 50%. In a subgroup of 42 patients resistant to both paclitaxel
and doxorubicin, the response rate was 29%. In the second study
(Blum et al, 1999b), which included 74 patients pretreated with
either paclitaxel or docetaxel, the response rate was 25% (27% in
patients pretreated with paclitaxel and 20% in patients pretreated
with docetaxel). The activity of capecitabine as second- or third-
line therapy thus compares favourably with trials of some other
agents reported in the literature. In a study of vinorelbine in
patients pretreated with paclitaxel, there were no responses (Fazeny
et al, 1996). Intermittent capecitabine therapy has also been evalu-
ated as ﬁrst-line treatment for breast cancer in a randomised, phase
II study in 95 women aged 555 years (O’Shaughnessy et al, 1998;
Aapro, 2000). The results indicated that capecitabine achieved a
response rate of 30%. Patients receiving the reference arm i.v. regi-
men of CMF achieved a response rate of 16% (not signiﬁcant). The
cumulative weight of this evidence indicates that capecitabine is an
effective agent for the treatment of breast cancer.
In the present study, capecitabine appeared to have safety bene-
ﬁts compared with paclitaxel. The majority of adverse events were
graded as mild or moderate in intensity. The most common side
effects of capecitabine therapy were diarrhoea, nausea, vomiting,
fatigue and hand–foot syndrome. Grade 3 adverse events were
reported in 23% of capecitabine patients, but only one patient
experienced a grade 4 adverse event. Of note, no signiﬁcant alope-
cia was reported in patients receiving capecitabine.
Myelosuppression was rare, with no cases of grade 2, 3 or 4 throm-
bocytopenia. Adverse events were controllable by treatment
interruption and, where necessary, dose reduction, along with
patient education and counselling. Furthermore, it has been shown
that efﬁcacy is not compromised if the dose is reduced from the
standard dose for adverse events (Hoff, 2000; O’Shaughnessy and
Blum, 2000). None of the patients was prematurely withdrawn
from the study due to treatment-related adverse events, and there
were no treatment-related deaths. The incidence of laboratory
abnormalities was very low, despite the high incidence of bone
and liver lesions. This safety proﬁle is very similar to that seen
in other clinical studies investigating capecitabine (O’Shaughnessy
et al, 1998; Blum, 1999; Blum et al, 1999a,b; Aapro, 2000; Van
Cutsem et al, 2000).
The safety proﬁle observed with paclitaxel, which was consistent
with the previous reports (Gelmon, 1994; Gelmon et al, 1999)
contrasted with that of capecitabine. Alopecia, peripheral neuropa-
thy and paraesthesia were common with paclitaxel. Alopecia was
reported in half of the paclitaxel group, with half of the cases clas-
siﬁed as grade 3. Myelosuppression, which is known to be the
dose-limiting side effect of this compound (Gelmon, 1994), was
common, with 53% of patients experiencing grade 3/4 neutropenia.
The convenient, oral administration of capecitabine combined
with its efﬁcacy and manageable toxicity proﬁle make it an attrac-
tive agent for outpatient use. Myelosuppression was rare, making
capecitabine a suitable agent for pretreated patients. Capecitabine
offers a convenient, patient-orientated therapy and enables patients
to control their treatment. Results of this study indicate that cape-
citabine achieves efﬁcacy in a similar range to that of paclitaxel,
and is well tolerated as treatment for metastatic breast cancer fail-
ing anthracycline therapy, while offering the advantages of oral
administration. Capecitabine is also being evaluated in combina-
tion with paclitaxel and docetaxel with the aim of increasing
efﬁcacy in patients with metastatic breast cancer.
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